A time bridge for obesity care: protein monitoring adds a timing layer to the EASO pathway while preserving the Lancet Commission definition

The European Association for the Study of Obesity (EASO) frames obesity care around staged, target-driven decisions. The Lancet Diabetes & Endocrinology Commission provides a disease definition-clinical obesity requires objective dysfunction- and distinguishes preventive strategies for preclinical obesity from therapeutic strategies for clinical obesity. Continuous protein monitoring (CPM) refers to wearable or minimally invasive sensors that repeatedly measure short panels of proteins in interstitial fluid or blood and track within-person trends over time. We hypothesize that CPM could help stratify risk and guide the timing of preventive intervention in preclinical obesity (excess adiposity, preserved function), and trigger timely escalation within the EASO pathway without changing the Commission's diagnostic criteria.